Elanco Animal Health Incorporated (NYSE:ELAN) Director William F. Doyle Acquires 15,000 Shares

Elanco Animal Health Incorporated (NYSE:ELAN) Director William F. Doyle purchased 15,000 shares of Elanco Animal Health stock in a transaction on Tuesday, May 21st. The stock was bought at an average cost of $16.98 per share, with a total value of $254,700.00. Following the completion of the acquisition, the director now owns 76,330 shares in the company, valued at $1,296,083.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Elanco Animal Health Stock Up 1.8 %

Shares of NYSE:ELAN opened at $16.79 on Friday. The company has a 50 day moving average of $15.20 and a 200-day moving average of $14.69. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.29 and a quick ratio of 1.96. Elanco Animal Health Incorporated has a one year low of $7.88 and a one year high of $17.43. The stock has a market cap of $8.30 billion, a price-to-earnings ratio of -6.34, a P/E/G ratio of 1.59 and a beta of 1.34.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.08. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter last year, the business earned $0.45 earnings per share. The company’s revenue was down 4.1% compared to the same quarter last year. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.93 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. Primecap Management Co. CA lifted its holdings in Elanco Animal Health by 2.9% during the fourth quarter. Primecap Management Co. CA now owns 50,600,324 shares of the company’s stock worth $753,945,000 after acquiring an additional 1,431,665 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Elanco Animal Health by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock worth $737,083,000 after purchasing an additional 467,196 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Elanco Animal Health by 4.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock worth $360,425,000 after purchasing an additional 852,281 shares during the period. Black Creek Investment Management Inc. grew its position in shares of Elanco Animal Health by 12.8% in the 3rd quarter. Black Creek Investment Management Inc. now owns 15,523,457 shares of the company’s stock valued at $174,484,000 after purchasing an additional 1,759,556 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Elanco Animal Health by 33.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 15,095,179 shares of the company’s stock valued at $224,920,000 after buying an additional 3,816,514 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $19.00 price objective (up from $18.00) on shares of Elanco Animal Health in a report on Monday, May 13th. Morgan Stanley lifted their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. TheStreet upgraded Elanco Animal Health from a “d+” rating to a “c-” rating in a research note on Friday, February 23rd. Barclays boosted their price target on Elanco Animal Health from $19.00 to $23.00 and gave the company an “overweight” rating in a research note on Thursday, May 9th. Finally, The Goldman Sachs Group increased their price objective on Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.29.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.